Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-amyrenone + beta-amyrenone (α,β-amyrenone) is a natural mixture of two pentacyclic triterpenes isolated from plants such as *Aleurites moluccana*. It functions as a small molecule therapeutic candidate with dual anti-inflammatory and metabolic regulatory properties. Preclinical studies indicate that the mixture reduces neutrophil migration and mechanical hypersensitivity in models of inflammation and arthritis. Furthermore, it demonstrates selective inhibition of alpha-glucosidase and pancreatic lipase, suggesting potential applications in the management of type 2 diabetes, obesity, and metabolic syndrome. Currently, it remains a research-stage compound without a commercial pharmaceutical developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-amyrenone + beta-amyrenone.